What is Evaxion?
Evaxion Biotech is a pioneering TechBio company that utilizes its advanced AI platform, AI-Immunology, to discover, design, and develop personalized vaccines for cancer and infectious diseases. The company focuses on decoding the human immune system to create novel vaccine candidates tailored to specific disease signatures. With a multidisciplinary team and state-of-the-art facilities, Evaxion aims to rapidly identify therapeutically relevant vaccine targets, enhancing the efficiency of vaccine development. Their innovative approach positions them at the forefront of the biotechnology industry, addressing the growing demand for effective treatments against critical diseases.
How much funding has Evaxion raised?
Evaxion has raised a total of $40M across 1 funding round:
Private Equity
$40M
Private Equity (2022): $40M with participation from Lincoln Park Capital
Key Investors in Evaxion
Lincoln Park Capital
Lincoln Park Capital is a Chicago-based investment group and asset management firm that specializes in opportunistic investing across public and private companies, real estate, and various money management strategies. With over a decade of experience, the firm focuses on growth and partnership opportunities.
What's next for Evaxion?
The recent major strategic investment signals a pivotal growth phase for Evaxion Biotech, likely enabling the company to accelerate its research and development pipeline, expand its clinical trials, and further commercialize its AI-driven personalized vaccine solutions. This capital infusion is expected to bolster their efforts in tackling complex diseases like cancer and infectious diseases, reinforcing their position as a leader in the biotechnology sector.
See full Evaxion company page
